Project Grant R01EY038843
Award Date 8/1/26
Completion Date 4/30/31
Dollars Obligated $670K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Eugene, OR 97403, USA
Similar Awards
- The National Eye Institute awarded The University of Iowa $641,479 for a Project Grant (R01EY037246) under the Vision Research program on May 1, 2026, to identify molecular signals leading to the onset and progression of Fuchs endothelial corneal dystrophy (FECD) phenotypes using a mouse model. The research addresses FECD, a blinding disease affecting 4–7% of individuals over 40 with an economic burden of $300 million annually. Corneal transplantation remains the prevalent treatment but...
- The National Eye Institute awarded the University of Cincinnati Sponsored Research Services $445,500 on June 1, 2026, under the Vision Research program (CFDA 93.867) to conduct fate mapping and functional analysis of COL8A2-positive cells in corneal endothelial development and disease. The recipient will generate a tamoxifen-inducible COL8A2P2A-CREERT2 mouse line to enable temporal and tissue-specific labeling and manipulation of COL8A2-positive cells. In Aim 1, the team will use lineage tracing...
- The National Institutes of Health National Eye Institute awarded S5G Therapeutics Inc. $313,373 on August 1, 2026, under the Vision Research program (CFDA 93.867) to develop a targeted pharmacotherapeutic preventing progression of Fuchs endothelial corneal dystrophy (FECD). The project aims to validate and determine feasibility of a non-surgical intervention that blocks ferroptosis-mediated death of corneal endothelial cells in FECD patients. Preliminary research conducted by S5G Therapeutics in...
- The National Eye Institute awarded Oregon Health & Science University $264,435 on May 1, 2026, under the Vision Research program (CFDA 93.867) to define the pathophysiology of microcephaly and chorioretinopathy (MCCRP) associated with defects in the gamma-tubulin ring complex. The project will use conditional knockout mouse models and tamoxifen-inducible endothelial cell-specific Cre recombinase to test the hypothesis that tubgcp4 and tubgcp6 serve critical roles in retinal and brain...
- The National Eye Institute awarded Kuria Therapeutics, Inc. $306,805 on September 1, 2026, under the Vision Research program (CFDA 93.867) to test SCO-116, an NRF2 activator, for efficacy in protecting corneal endothelial cells against oxidative stress in Fuchs' corneal endothelial dystrophy. The award funds Phase 1 research to establish proof of concept using cultured human corneas as a model system. The work comprises two specific aims: testing a range of SCO-116 concentrations for NRF2...
- Federal Project Grant Award Summary The National Eye Institute (NEI), under its Vision Research program (CFDA 93.867), awarded The Ohio State University $433,125 on August 1, 2025, to investigate tissue factor (TF) as a potential biomarker and therapeutic target for corneal neovascularization (CNV). This two-year project, concluding July 31, 2027, addresses a significant unmet medical need, as CNV—the pathological growth of blood vessels in the cornea—is a common sequela of corneal diseases...
- The National Eye Institute awarded the University of Utah $620,926 on September 1, 2026, under the Vision Research program (CFDA 93.867) to develop an engineered human cornea chip for studying keratoconus pathology. The project investigates curvature-dependent cellular responses in corneal epithelial, stromal, and endothelial cells using a microfabricated organ chip platform. Work focuses on three specific aims: identifying mechanotransduction pathways and validating therapeutic targets...
- The National Eye Institute awarded New York University $546,439 on April 15, 2026, under the Vision Research program (CFDA 93.867) to develop corneal stromal keratocyte modeling from human cornea organoids as a potential therapy for corneal blindness caused by stromal scarring, infection, and keratoconus. The research focuses on generating human cornea organoids from induced pluripotent stem cells that mimic the fetal cornea and co-differentiate stromal keratocytes, epithelial, and endothelial...
- The National Eye Institute awarded Oregon Health & Science University $237,341 on August 1, 2026, to develop curvature and color correction techniques for ultrawidefield optical coherence tomography imaging of the retina under the Vision Research program (CFDA 93.867). The project addresses fundamental limitations in current OCT technology by applying GPU-accelerated ray tracing for geometric reconstruction of the retina to eliminate distortion and curvature artifacts in widefield imaging,...
- The National Eye Institute awarded Oregon Health & Science University $498,180 on September 1, 2026, under the Vision Research program (CFDA 93.867) to develop and apply novel optical coherence tomography (OCT) methods for detecting and monitoring photoreceptor changes associated with age-related macular degeneration. The project runs through August 31, 2030, with performance based in Portland, Oregon. Aim 1 investigates cone photoreceptor function impairments in AMD through advancement of...